▶ SURVODUTIDE · SUBTOPIC · DOSING LITERATURE

SURVODUTIDE Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of SURVODUTIDE. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for SURVODUTIDE reports the following route(s) of administration: Subcutaneous (Phase 3 clinical). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of SURVODUTIDE.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for SURVODUTIDE of approximately ~7 days (once-weekly). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of SURVODUTIDE. Refer to the original publication for full protocol detail.

• Le Roux CW, et al. (2024) reports the SURVODUTIDE protocol used in Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial, published in Lancet Diabetes Endocrinol. PMID 38219768. See the source for the protocol-level dose range, frequency, and duration. link
• Boehringer Ingelheim (2024) reports the SURVODUTIDE protocol used in A study of survodutide in adults with overweight or obesity (SYNCHRONIZE-1), published in ClinicalTrials.gov · Phase 3. NCT06066515. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · -20 °C 24 months

Reconstituted · 2-8 °C, 28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Investigational. Phase 3 SYNCHRONIZE-1/2 obesity trials enrolling.

WADA · Not currently listed on the WADA Prohibited List.

RELATED PAGES

▶ LAST UPDATED · 2026-05-19